Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

被引:2
|
作者
Vonk, Steffie E. M. [1 ]
Altenburg, Josje [2 ]
Mathot, Ron A. A. [1 ]
Kemper, E. Marleen [1 ,3 ]
机构
[1] Univ Amsterdam, Dept Hosp Pharm & Clin Pharmacol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Pulm Med, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC, Amsterdam, Netherlands
关键词
Elexacaftor-tezacaftor-ivacaftor; Therapeutic drug monitoring; Area under the curve; Trough concentration; CFTR modulators;
D O I
10.1016/j.jcf.2024.03.010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Therapeutic drug monitoring (TDM) of elexacaftor, tezacaftor, ivacaftor (ETI) could be a useful tool to increase efficacy and decrease the risk of adverse effects in people with Cystic Fibrosis (pwCF). It is however unclear whether drug exposure should be monitored by assessment of trough (C-min) levels or determination of the area under the curve (AUC). Hence, in this study the correlation between measured C min concentration and AUC was evaluated. Serial plasma samples, including C-min , were drawn after administration of ETI in order to calculate the AUC and assess the correlation between the two parameters. A linear correlation between C- min and AUC 0-24h was found, with Pearson's r correlation coefficients of 0.963, 0.908 and 0.860 for elexacaftor, tezacaftor and ivacaftor, respectively. Exposure of ETI may be monitored by assessment of C( min )levels.
引用
收藏
页码:1007 / 1009
页数:3
相关论文
共 50 条
  • [1] Elexacaftor/Ivacaftor/Tezacaftor(Trikafta)
    贾宏伟
    程卯生
    中国药物化学杂志, 2020, 30 (09) : 582 - 582
  • [2] Elexacaftor/Ivacaftor/Tezacaftor: First Approval
    Sheridan M. Hoy
    Drugs, 2019, 79 : 2001 - 2007
  • [3] Elexacaftor/Ivacaftor/Tezacaftor: First Approval
    Hoy, Sheridan M.
    DRUGS, 2019, 79 (18) : 2001 - 2007
  • [4] Elexacaftor/tezacaftor/ivacaftor outpatient desensitization
    Balijepally, Ramya
    Kwong, Denise
    Zhu, Linda
    Camacho, Juanita Valdes
    Liu, Anne
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (01) : 104 - 105
  • [5] Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy
    Cimino, Giuseppe
    Sorrenti, Sara
    Murciano, Manuel
    Galoppi, Paola
    Ascenzioni, Fiorentina
    Botta, Bruno
    Brunelli, Roberto
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2024, 309 (01) : 9 - 15
  • [6] Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy
    Giuseppe Cimino
    Sara Sorrenti
    Manuel Murciano
    Paola Galoppi
    Fiorentina Ascenzioni
    Bruno Botta
    Roberto Brunelli
    Archives of Gynecology and Obstetrics, 2024, 309 : 9 - 15
  • [7] Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor
    Middleton, Peter G.
    Simmonds, Nicholas J.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (03)
  • [8] Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1589): : 5 - 7
  • [9] CRS in CF - Therapy with Ivacaftor/Tezacaftor/Elexacaftor
    Appel, H.
    Rapp, H.
    Bode, S.
    Fabricius, D.
    ALLERGOLOGIE, 2022, 45 (08) : 609 - 610